Press Conference – Melbourne

GREG HUNT: Thank you everybody for joining us, I’m joined by Professor Brendan Murphy, the Chief Medical Officer of Australia this afternoon. Under the Prime Minister’s leadership, the National Security Council has met and made decisions to lift the travel advisories for Iran and to impose certain restrictions as a consequence of the spread of…

Government strengthens support for melanoma patients, with breakthrough treatment expanded on PBS

The start of autumn will bring with it a new sense of hope for over 2,000 Australians with advanced melanoma, with the Morrison Government expanding subsidised access to a breakthrough melanoma treatment option on the Pharmaceutical Benefits Scheme (PBS) from today.   On March 1, the current PBS listing of Opdivo® (nivolumab) will be expanded…

Greater support for Australians with an intellectual disability

Australians with an intellectual disability will soon receive greater support, thanks to a Morrison Government $6.5 million investment in the Primary Care Enhancement Program.   The funding (GST exclusive) will be provided over four financial years (2020-21 to 2023-24) under the Primary Health Networks (PHN) Program, for development of the Primary Care Enhancement Program (PCEP).…

$2 million for vital coronavirus research

Applications have opened for the Australian Government’s $2 million grant opportunity to support research into development of a vaccine to protect against novel coronavirus (COVID-19). COVID-19 represents a significant and urgent threat to global health, with the overwhelming majority of cases in Wuhan City in China, and increasing numbers in other countries, including Australia. The…

New hope for lung cancer patients with ground-breaking treatment option to be listed on the PBS

Australians with non-small cell and small cell lung cancer or chronic obstructive pulmonary disease (COPD) will benefit from new and expanded treatment options on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2020.   The Morrison Government is listing Imfinzi® (durvalumab) for the first time for the treatment of non‑small cell lung cancer for patients who…